Trial results for the study NCT06003075, investigating nivolumab in combination with chemotherapy for unresectable Stage III non-small cell lung cancer (NSCLC), were posted on ClinicalTrials.gov on 2025-04-30. The study, titled "Induction Chemo-Nivo in Unresectable Stage III NSCLC," was terminated early after enrolling only 1 participant.
Background
Nivolumab is a drug that has been investigated across various cancer types. This particular study explored its use in patients with Lung Cancer, Nonsmall Cell, specifically those with Lung Cancer Stage III that is unresectable.
Trial design
The study NCT06003075 was a Phase 2 trial with an overall status of TERMINATED. It aimed to determine the response rate, safety, and effectiveness of a combination therapy in patients with lung cancer. The trial enrolled 1 participant and focused on individuals with Lung Cancer, Nonsmall Cell and Lung Cancer Stage III. Interventions included nivolumab and chemotherapy, as well as nivolumab alone.
What this means
The early termination of this Phase 2 trial with only 1 enrolled participant means that no meaningful efficacy or safety data can be drawn from this study regarding nivolumab and chemotherapy for unresectable Stage III NSCLC. The termination prevents the collection of sufficient data to assess the study's stated purpose of determining response rate, safety, and effectiveness.
Source
The information regarding the termination of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT06003075, titled "Induction Chemo-Nivo in Unresectable Stage III NSCLC," were posted on 2025-04-30 on clinicaltrials.gov.